These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 24073234)

  • 1. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.
    Duka V; Lee JH; Credle J; Wills J; Oaks A; Smolinsky C; Shah K; Mash DC; Masliah E; Sidhu A
    PLoS One; 2013; 8(9):e75025. PubMed ID: 24073234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.
    Haggerty T; Credle J; Rodriguez O; Wills J; Oaks AW; Masliah E; Sidhu A
    Eur J Neurosci; 2011 May; 33(9):1598-610. PubMed ID: 21453448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
    Muntané G; Dalfó E; Martinez A; Ferrer I
    Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
    Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
    Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein.
    Goedert M
    Science; 2015 Aug; 349(6248):1255555. PubMed ID: 26250687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
    Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
    J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.
    Walker L; McAleese KE; Thomas AJ; Johnson M; Martin-Ruiz C; Parker C; Colloby SJ; Jellinger K; Attems J
    Acta Neuropathol; 2015 May; 129(5):729-48. PubMed ID: 25758940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.
    Ho CY; Troncoso JC; Knox D; Stark W; Eberhart CG
    Brain Pathol; 2014 Jan; 24(1):25-32. PubMed ID: 23714377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
    Sierra M; Gelpi E; Martí MJ; Compta Y
    Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroinflammation and protein pathology in Parkinson's disease dementia.
    Kouli A; Camacho M; Allinson K; Williams-Gray CH
    Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities.
    Orad RI; Shiner T
    J Neurol; 2022 Feb; 269(2):639-653. PubMed ID: 33511432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.
    Duka T; Duka V; Joyce JN; Sidhu A
    FASEB J; 2009 Sep; 23(9):2820-30. PubMed ID: 19369384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau maturation in the clinicopathological spectrum of Lewy body and Alzheimer's disease.
    Arezoumandan S; Cousins KAQ; Ohm DT; Lowe M; Chen M; Gee J; Phillips JS; McMillan CT; Luk KC; Deik A; Spindler MA; Tropea TF; Weintraub D; Wolk DA; Grossman M; Lee V; Chen-Plotkin AS; Lee EB; Irwin DJ
    Ann Clin Transl Neurol; 2024 Mar; 11(3):673-685. PubMed ID: 38263854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein.
    Harrington CR; Perry RH; Perry EK; Hurt J; McKeith IG; Roth M; Wischik CM
    Dementia; 1994; 5(5):215-28. PubMed ID: 7951676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.
    Irwin DJ; Grossman M; Weintraub D; Hurtig HI; Duda JE; Xie SX; Lee EB; Van Deerlin VM; Lopez OL; Kofler JK; Nelson PT; Jicha GA; Woltjer R; Quinn JF; Kaye J; Leverenz JB; Tsuang D; Longfellow K; Yearout D; Kukull W; Keene CD; Montine TJ; Zabetian CP; Trojanowski JQ
    Lancet Neurol; 2017 Jan; 16(1):55-65. PubMed ID: 27979356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.
    Wills J; Jones J; Haggerty T; Duka V; Joyce JN; Sidhu A
    Exp Neurol; 2010 Sep; 225(1):210-8. PubMed ID: 20599975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology.
    de Pablo-Fernández E; Courtney R; Rockliffe A; Gentleman S; Holton JL; Warner TT
    Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1080-1091. PubMed ID: 33969516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores.
    Bayer TA; Jäkälä P; Hartmann T; Havas L; McLean C; Culvenor JG; Li QX; Masters CL; Falkai P; Beyreuther K
    Neurosci Lett; 1999 May; 266(3):213-6. PubMed ID: 10465711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.